B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 7904670.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.
Medical subject headings
- Blood Coagulation Factors
- Blood Component Transfusion
- DNA, Viral
- Erythema Infectiosum
- Hemophilia A
- Immunocompromised Host
- Infection Control
- Parvovirus B19, Human